Abstract:Among the hallmarks of cholangiocarcinoma (CCA) progression and unresponsiveness to therapy is impaired ubiquitin-dependent degradation of nuclear tumor suppressor protein. In the previous stage, our research group found that as a key tumor suppressor, nuclear dysfunction of p27kip1 is closely related to chemotherapy resistance of CCA, but the specific mechanism is unclear. It was recently shown that p27kip1-driven tumors were strongly dependent on the SUMO pathway. RNF4, as the SUMO-targeted ubiquitin ligase (STUbL), identifies SUMOylated proteins as a substrate through sumo-interacting motifs (SIM) and causes its degradation via the ubiquitin proteasome pathway. Here we described that the expression of RNF4 was upregulated in CCA tissues and related to malignant features. Silencing RNF4 arrested human CCA cells at the G1 phase, which was associated with the upregulation of p27kip1 and the downregulation of its downstream cycle-related proteins. Silencing RNF4 inhibited cell proliferation and migration, increased cell apoptosis, and sensitized CCA cells to treatment of chemotherapeutic drugs in vitro. Immunofluorescence showed that p27kip1 and RNF4 were mainly co-located in the nucleus. Immunoprecipitation and Western blot showed that p27kip1 was a target protein for SUMOylation and high expression of RNF4 decreased the levels of nuclear p27kip1, enhanced the levels of ubiquitinated and SUMOylated p27kip1, indicating that RNF4 could regulate cell cycle progression via recognizing SUMOylated p27kip1 and facilitating its ubiquitination degradation. These data indicate that RNF4-mediated ubiquitination degradation of SUMOylated proteins is a novel regulatory mechanism of p27kip1 dysfunction and CCA tumorigenesis, which provides a potential option for therapeutic intervention of CCA.

RNF4 negatively regulates NF-κB signaling by down-regulating TAB2

RNF4 Negatively Regulates NF‐κB Signaling by Down‐regulating TAB2

RBCK1 Negatively Regulates Tumor Necrosis Factor- and Interleukin-1-triggered NF-κB Activation by Targeting TAB2/3 for Degradation

A Study of Mechanism of Modulation of NF-κB Activity of HepG2 Cells by BC047440 Genes

Ubiquitin-associated Domain-containing Ubiquitin Regulatory X (UBX) Protein UBXN1 is a Negative Regulator of Nuclear Factor Κb (Nf-Κb) Signaling*

The E3 Ligase RNF34 is a Novel Negative Regulator of the NOD1 Pathway

Trim30 Alpha Negatively Regulates Tlr-Mediated Nf-Kappa B Activation By Targeting Tab2 And Tab3 For Degradation

RNF144B inhibits LPS-induced inflammatory responses via binding TBK1

TRIM30α negatively regulates TLR-mediated NF-κB activation by targeting TAB2 and TAB3 for degradation

NUMBL interacts with TAB2 and inhibits TNFalpha and IL-1beta-induced NF-kappaB activation

E3 ligase RNF99 negatively regulates TLR-mediated inflammatory immune response via K48-linked ubiquitination of TAB2

NLRC5 Negatively Regulates the NF-κB and Type I Interferon Signaling Pathways

TRIM 30 a negatively regulates TLR-mediated NF-j B activation by targeting TAB 2 and TAB 3 for degradation

RNF149 negatively regulates LPS/TLR4 signal transduction by ubiquitination-mediated CD63 degradation

USP18 negatively regulates NF-κB signaling by targeting TAK1 and NEMO for deubiquitination through distinct mechanisms

Ring Finger Protein 31–mediated Atypical Ubiquitination Stabilizes Forkhead Box P3 and Thereby Stimulates Regulatory T-cell Function

RNF4 promotes tumorigenesis, therapy resistance of cholangiocarcinoma and affects cell cycle by regulating the ubiquitination degradation of p27kip1 in the nucleus

NLRC5 negatively regulates the NF-kappaB and type I interferon signaling pathways

LRRC14 Attenuates Toll-like Receptor-Mediated NF-κB Signaling Through Disruption of IKK Complex.

WDR34 is a Novel TAK1-associated Suppressor of the IL-1R/TLR3/TLR4-induced NF-κB Activation Pathway

LATS2 Inhibits the Activity of NF-κ B Signaling by Disrupting the Interaction Between TAK1 and IKKβ